Hamel Associates Inc. Has $3.76 Million Stake in Pfizer Inc. (NYSE:PFE)

Hamel Associates Inc. lifted its position in Pfizer Inc. (NYSE:PFE) by 3.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 130,018 shares of the biopharmaceutical company’s stock after purchasing an additional 4,410 shares during the quarter. Hamel Associates Inc.’s holdings in Pfizer were worth $3,763,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of PFE. China Universal Asset Management Co. Ltd. acquired a new position in shares of Pfizer in the first quarter valued at $315,000. GSA Capital Partners LLP acquired a new position in Pfizer during the first quarter worth $439,000. Koshinski Asset Management Inc. raised its stake in Pfizer by 20.5% during the first quarter. Koshinski Asset Management Inc. now owns 24,265 shares of the biopharmaceutical company’s stock worth $673,000 after acquiring an additional 4,130 shares in the last quarter. Dearborn Partners LLC raised its stake in Pfizer by 18.4% during the first quarter. Dearborn Partners LLC now owns 32,683 shares of the biopharmaceutical company’s stock worth $907,000 after acquiring an additional 5,077 shares in the last quarter. Finally, Private Management Group Inc. raised its stake in Pfizer by 270.7% during the first quarter. Private Management Group Inc. now owns 26,579 shares of the biopharmaceutical company’s stock worth $738,000 after acquiring an additional 19,409 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PFE has been the subject of several recent analyst reports. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Sanford C. Bernstein started coverage on Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Citigroup started coverage on Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price for the company. Eight research analysts have rated the stock with a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Price Performance

Shares of PFE stock opened at $26.18 on Wednesday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $31.54. The firm has a market cap of $148.36 billion, a price-to-earnings ratio of 35.38, a PEG ratio of 0.83 and a beta of 0.67. The stock has a 50-day moving average price of $28.80 and a 200 day moving average price of $28.68.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter last year, the business earned ($0.17) earnings per share. The company’s revenue was up 31.2% compared to the same quarter last year. Research analysts expect that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.42%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Insider Activity

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by company insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.